Trial Profile
A multicenter dosimetry trial to evaluate radiation absorbed dose from holmium-166-DOTMP in patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Holmium-166-DOTMP (Primary) ; Melphalan
- Indications Multiple myeloma; Smoldering multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2005 New trial record.